Halozyme Therapeutics | HALO - Current Liabilities


Halozyme Therapeutics reported $177.09M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 194.46M 12.23M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Baxter International USD 2.97B 805M Dec/2025
Cara Therapeutics USD 11.04M 362K Sep/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
DBV Technologies USD 49.48M 60K Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
MannKind USD 171.03M 61.9M Dec/2025
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025